Mutant amyloid-beta-sensitized dendritic cells as Alzheimer's disease vaccine

Abstract

Vaccines using bone marrow-derived dendritic cells (DCs) sensitized to Abeta 1-42 peptide and other mutant peptides were tested on BALB/c and APP(SW) transgenic mice. Wild type Abeta 1-42-sensitized DC vaccine (DCSV) produced no response, but all peptides with a T-cell epitope mutation induced antibody responses without inflammation. DCSV with Abeta 1-25 peptide with mutated T-cell epitope failed to induce antibody response, while DCSV with Abeta 1-35 with mutated T-cell epitope produced a strong antibody response. The entire T-cell epitope is required in a DC vaccine to induce antibody response. DCSV with Abeta peptide carrying the entire mutant T-cell epitope may be an appropriate vaccine against AD.